BROADER
HEALTH
BENEFITS

Viral suppression with oral ART was the first step, now it’s time to take your patients further

With 6 doses per year, following initiation,[1,2] 2-monthly VOCABRIA + REKAMBYS enables people living with HIV the opportunity to thrive through high adherence and treatment satisfaction vs regular daily orals[3-7]

People living with HIV showed high adherence to VOCABRIA + REKAMBYS, across clinical trials and real-world settings[3,5,7–9]

High adherence to injection visits demonstrated up to 3 years in clinical trials:

*QM CABOTEGRAVIR + RILPIVIRINE is not available in the UK.

SOLAR study design

Read more

CARES study design

Read more

ATLAS-2M study design

Read more

High adherence to injection visits was also shown in up to 2 years of real-world evidence:[8]

SCohoLART

Month 24
98% (n=5,276/5,376) of injection visits occurred within the Flexible Dosing Window for people living with HIV receiving 2-monthly VOCABRIA + REKAMBYS

High adherence was also demonstrated in a real-world study that included people living with HIV with complex medical needs, social vulnerability, and/or historical non-adherence:[9]

JABS

Month 12
97% (n=384/395) of injection visits occurred within the Flexible Dosing Window for people living with HIV receiving 2-monthly VOCABRIA + REKAMBYS (primary endpoint)

These studies report adherence rates based on the number of injections received in the Flexible Dosing Window, defined as ±7 days from the Target Treatment Date.

Greater retention and engagement with care shown in people living with HIV receiving VOCABRIA + REKAMBYS vs regular daily oral therapy[10,11]

Retention and engagement in care can be important factors for improving outcomes for people living with HIV. Evidence shows that patient engagement in care can lead to a reduction in the number of hospitalisations; improved effectiveness, efficiency, quality of health services; and improved quality of life.[12]

Retention in care

The real-world OPERA cohort study found that more people living with HIV receiving VOCABRIA + REKAMBYS were retained in care* at ≥12 months follow-up than those receiving regular daily oral therapy.[10]

Engagement with care

In the real-world ABOVE study, people living with HIV receiving VOCABRIA + REKAMBYS had higher rates of key preventative measures vs those remaining on regular daily oral therapy, including:†[11]

  • rates of vaccinations
  • cancer screenings
  • STI screenings
  • bone density testing

The SOLAR primary endpoint was met: 2-monthly VOCABRIA + REKAMBYS was non-inferior to BIC/FTC/TAF at Month 12 (mITT-E: 1% [n=5/447] with plasma HIV-1 RNA ≥50 copies/mL vs 0.4% [n=1/223], respectively; adjusted difference = 0.7% [95% CI: -0.7%, 2.0%]; 4% non-inferiority margin).[3]
The ATLAS-2M primary endpoint was met: 2-monthly VOCABRIA + REKAMBYS was non-inferior to 1-monthly VOCABRIA + REKAMBYS at week 48 (ITTE: 2% (n=9/522) with plasma HIV RNA ≥50 copies/mL vs 1% (n=5/523), respectively; adjusted difference 0.8% (95% CI: -0.6% to 2.2%); 4% non-inferiority margin.[13]
The CARES primary endpoint was met: 2-monthly VOCABRIA + REKAMBYS was non-inferior to daily oral therapy at Week 48 (ITT-E: 96% [n=246/255] with plasma HIV-1 RNA <50 copies/mL vs 97% [n=250/257], respectively; adjusted difference = -0.8% [95% CI: -3.7%, 2.3%]; -10% non-inferiority margin).[14]
The SCohoLART primary end point was: The cumulative proportion of people experiencing TD over 12 months. TD was considered at the occurrence of VF, defined as 2 consecutive HIV RNA levels ≥50 copies/mL or a single level ≥1000 copies/mL after initiation of long-acting CAB/RPV or at switching to another regimen for any reason. During a median time study follow-up time (IQR) of 13.1 (9.1–15.5) months, 52 PWH (10.1%) experienced TD; the median time to TD was 5.1 (2.7–8.9) months.
*CDC’s definition of retention in care: two or more viral load or CD4 tests per year, ≥3 months apart.[10]
†Compared to daily oral therapy, VOCABRIA + REKAMBYS was associated with higher rates for key preventative measures, including: rates of vaccinations (overall rate ratio [RR] 1.25 [95% CI: 1.18, 1.33]), cancer screenings (overall RR 1.17 [95% CI: 1.07, 1.28]), STI screenings (RR 1.24 [95% CI: 1.09, 1.40]), and bone density tests (RR 2.37 [95% CI: 1.64, 3.42]) (p<0.001).[11]

Involvement in treatment decisions and satisfaction with care empowers people living with HIV to take charge of their own health, adhere to treatment and remain in care[15,16]

Explore how VOCABRIA + REKAMBYS may benefit people living with HIV, beyond viral suppression:

Patient preference

Read more

Clinical considerations

Read more

Treatment satisfaction

Read more

Contact us for support

ABC/3TC=abacavir/lamivudine; ART=antiretroviral therapy; BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; CDC=Centers for Disease Control; CD4=cluster of differentiation 4; CI=confidence interval; HIV=human immunodeficiency virus; HIV-1=human immunodeficiency virus type 1; IQR=interquartile range; ITT-E=intention-to-treat exposed; mITT-E=modified intention-to-treat exposed; RNA=ribonucleic acid; RR=rate ratio; STI=sexually transmitted infection.

References:

  1. VOCABRIA (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC).
  2. REKAMBYS (rilpivirine) 900 mg suspension for injection Summary of Product Characteristics (SmPC).
  3. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566–e577. doi: 10.1016/S2352-3018(23)00136-4.
  4. Wyen C, Noe S, Jonsson-Oldenbüttel C, et al. 24-Month Outcomes of Cabotegravir Plus Rilpivirine Long-Acting Every 2 Months in a Real-World Setting: Effectiveness, Adherence to Injections, and Patient-Reported Outcomes From People With HIV-1 in the German CARLOS Study. Presented at: The 13th International AIDS Society (IAS) Conference; July 13–17, 2025; Kigali, Rwanda. Poster TUPEB035.
  5. Kityo C, Mambule IK, Sokhela S, et al. Randomized trial of Cabotegravir and Rilpivirine Long-acting in Africa (CARES): Week 96 Results. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 9–12, 2025; San Francisco, California, USA. Oral abstract 00202.
  6. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomized, multicentre, open-label, phase 3b, non-inferiority study. Published in Lancet. 2021; Vol. 396, Issue 10267, Pages 1994–2005. DOI: 10.1016/S0140-6736(20)32666-0.
  7. Overton ET, Richmond G, Rizzardini G, et al. Long-acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 (HIV-1) Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-label, Phase 3b Noninferiority Study. Clin Infect Dis. 2023;76(9):1646–1654.
  8. Muccini C, Capra N, Lolatto R, et al. Two-years efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART study. Presented at: The Italian Conference on AIDS and Antiviral Research (ICAR); May 21–23, 2025; Padua, Italy. Oral presentation OC35.
  9. John M, Williams L, Nolan G, et al. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS). HIV Med. 2024;25(8):935–945. doi: 10.1111/hiv.13647. 
  10. Lackey PC, Weber RP, Pierone G, Jr, et al. Increased Screening for Sexually Transmitted Infections and HIV Surrogate Marker Testing Among Long-Acting Injectable Versus Daily Oral ART Antiretroviral Therapy Users in the OPERA Cohort. Presented at: The 25th International AIDS Conference; July 22–26, 2024; Munich, Germany. Poster WEPEC319.
  11. Garris C, Desai R, Chang R, et al. Comparative Analysis of Screening and Preventative Measures and Healthcare Resource Utilization Among People with HIV Receiving Long-Acting Cabotegravir Plus Rilpiverine or Oral Antiretroviral Therapy in the US: The ABOVE Study. Presented at: Academy of Managed Care Pharmacy Annual Meeting; March 31–April 3, 2025. Houston, Texas, USA. Poster B6.
  12. Marzban S, Najafi M, Agolli A, et al. Impact of Patient Engagement on Healthcare Quality: A Scoping Review. J Patient Exp. 2022;16:9: 23743735221125439. doi: 10.1177/23743735221125439.
  13. Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7.
  14. Kityo C, Mambule IK, Musaazi J, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024;24(10):1083–1092. doi: 10.1016/S1473-3099(24)00289-5.
  15. Okoli C, Brough G, Allan B, et al. Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV. AIDS Behav. 2021;25(5):1384–1395. doi: 10.1007/s10461-020-02973-4.
  16. Keelson SA, Addo JO, Amoah J. The impact of patient engagement on service quality and customer well-being: an introspective analysis from the healthcare providers’ perspective. Cogent Public Health. 2024;11(1):2340157. doi: 10.1080/27707571.2024.2340157.

REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.

PM-GB-CBR-WCNT-250010 | March 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.